Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
View through CrossRef
<p>Figure S1A. Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B. Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C. Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D. Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E. Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F. Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A. Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B. Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C. Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>
American Association for Cancer Research (AACR)
Title: supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Description:
<p>Figure S1A.
Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B.
Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C.
Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D.
Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E.
Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F.
Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A.
Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B.
Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C.
Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>.
Related Results
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<div>Abstract<p>Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumo...
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Abstract
Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor...
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<div>Abstract<p>Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumo...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<p>Figure S1A. Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B. Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-trea...
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract
Background: The etiology of melanoma has generally been thought to be exposure to UV radiation (sun and sun tanning lamps). However, the percent of melanoma...
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant ...
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a point where very modest subset...